At the news
? NEUTRALIMPACT 3/10 6-K filed Aug 3, 2026 at 06:54 ET
BioNTech announced the appointment of Guido Oelkers as CEO, effective by February 1, 2027, succeeding co-founder Prof. Ugur Sahin. Oelkers joins from Sobi with a track record of scaling biopharma operations. The filing signals a planned leadership transition as the company focuses on its late-stage oncology pipeline; no financial data or guidance was provided.
- Guido Oelkers appointed CEO, to take office by February 1, 2027
- Oelkers succeeds co-founder Prof. Ugur Sahin, who will transition to lead a new independent company with CMO Prof. Özlem Türeci
- Search for a successor CMO is ongoing
- Oelkers previously served as CEO of Sobi (2017-2026), where revenues more than quadrupled
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access